268 related articles for article (PubMed ID: 17555561)
1. Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A; Urruticoechea A; Dixon JM; Dexter T; Fenwick K; Ashworth A; Drury S; Larionov A; Young O; White S; Miller WR; Evans DB; Dowsett M
Breast Cancer Res; 2007; 9(3):R37. PubMed ID: 17555561
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
4. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
[TBL] [Abstract][Full Text] [Related]
5. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
6. A decade of letrozole: FACE.
O'Shaughnessy J
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
9. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
[TBL] [Abstract][Full Text] [Related]
10. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
11. Primary hormone treatment in postmenopausal women with breast cancer.
Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
[TBL] [Abstract][Full Text] [Related]
12. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Turnbull AK; Arthur LM; Renshaw L; Larionov AA; Kay C; Dunbier AK; Thomas JS; Dowsett M; Sims AH; Dixon JM
J Clin Oncol; 2015 Jul; 33(20):2270-8. PubMed ID: 26033813
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
14. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
15. Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Lu Y; You M; Ghazoui Z; Liu P; Vedell PT; Wen W; Bode AM; Grubbs CJ; Lubet RA
Cancer Prev Res (Phila); 2013 Nov; 6(11):1151-61. PubMed ID: 24067424
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Sendur MA; Aksoy S; Zengin N; Altundag K
Br J Cancer; 2012 Nov; 107(11):1815-9. PubMed ID: 23099804
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
18. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Mouridsen H; Gershanovich M
Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
